Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: BACTROBAN

« Back to Dashboard
Bactroban is a drug marketed by Glaxosmithkline and is included in three NDAs. It is available from seven suppliers. There is one patent protecting this drug.

This drug has forty patent family members in thirty countries.

The generic ingredient in BACTROBAN is mupirocin. There are eleven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mupirocin profile page.

Summary for Tradename: BACTROBAN

Suppliers / Packagers: see list14

Pharmacology for Tradename: BACTROBAN

Clinical Trials for: BACTROBAN

A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.
Status: Completed Condition: Secondarily Infected Traumatic Skin Lesions

Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
Status: Completed Condition: Staphylococcal Infection

Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection
Status: Completed Condition: Staphylococcus Aureus; HIV Infections

Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting
Status: Completed Condition: Surgical Site Infections

Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin
Status: Completed Condition: Surgical Site Infection

Preventing Staphylococcal (Staph) Infection
Status: Completed Condition: Staphylococcal Infections

Safety and Efficacy of Intranasal and Topical Mupirocin in Eradicating Colonization With Staphylococcus Aureus (SA) in Critically Ill Infants - a Phase 2, Multi-Center, Open Label, Randomized Trial
Status: Recruiting Condition: Staphylococcal Infection

Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection
Status: Not yet recruiting Condition: End Stage Renal Disease; Peritoneal Dialysis

Topical Gentamicin Cream Versus Alternating Gentamicin and Mupirocin Cream in Peritoneal Dialysis
Status: Not yet recruiting Condition: Rate of Exit Site Infection; Rate of Atypical Mycobacterial Infection; Rate of Peritoneal Dialysis

Total Occlusive Ionic Silver-containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection
Status: Completed Condition: Incisional Surgical Site Infections

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
mupirocin calcium
CREAM;TOPICAL050746-001Dec 11, 1997RXYes6,025,389<disabled>Y <disabled>
mupirocin calcium
OINTMENT;NASAL050703-001Sep 18, 1995RXYes<disabled><disabled>
OINTMENT;TOPICAL050591-001Dec 31, 1987RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: BACTROBAN

Country Document Number Publication Date
JapanH09506865Jul 08, 1997
Slovenia727979Oct 31, 2001
Poland177592Dec 31, 1999
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn